Recent FDA approvals and therapies under FDA review are adding new treatments to the armamentarium, said Paul Hahn, MD, vitreoretinal surgeon at NJRetina.
Recent FDA approvals and therapies under FDA review are adding new treatments to the armamentarium, said Paul Hahn, MD, vitreoretinal surgeon at NJRetina.
Transcript
In the current ASRS Preferences and Trends survey, were there any novel therapies that respondents were excited about?
Just like technology, this field of retina has been rife with changes in therapies. Over the past year, there was the FDA approval of this sustained delivery surgical implant for wet AMD [age-related macular degeneration]. The response has been kind of mixed, with some being very excited and some being not so excited. Again, I think that the place for this device has yet to be determined, but in my opinion, has an important place in our treatment armamentarium.
Since the survey was actually released, there was the FDA approval of another novel therapeutic agent, a bispecific anti-VEGF [vascular endothelial growth factor] anti–Ang-2 inhibitor—the first of its kind. Retina specialists in the survey were most excited about its potential for extended durability, and certainly, in the next upcoming year’s survey, we'll poll the retina specialists to see what the temperature is and what their utilization is on this new drug.
Perhaps also very exciting, under current FDA review, is the first potential treatment for geographic atrophy and dry macular degeneration. At the time of the survey, results were somewhat mixed, with some retina specialists being enthusiastic about it and some being somewhat lukewarm. Since the survey, some more favorable results have been released, and it would be very interesting to see if that moves the needle. By the time of next year’s survey, we may likely have information as to whether or not this drug is FDA approved, and we'll certainly poll retina specialists to see what their thoughts are on this
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More